Leerink Partners maintained its "Outperform" rating for Arcturus Therapeutics (ARCT). The firm increased its price target from $13.00 to $19.00. This marks a 46.15% increase.
The rating update reflects the company's continued advancement of its mRNA-based therapeutic pipeline. Arcturus presented at several investor conferences in September. The company provided updates on key programs, including its Phase 2 asset for ornithine transcarbamylase (OTC) deficiency.